Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.1%. By the end of trading, Biogen Idec rose $4.42 (2.1%) to $214.13 on light volume. Throughout the day, 838,706 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,417,400 shares. The stock ranged in a price between $209.03-$217.07 after having opened the day at $209.19 as compared to the previous trading day's close of $209.71. Other companies within the Drugs industry that increased today were:
), up 33.1%,
), up 15.4%,
), up 8.6% and
), up 8.0%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $50.5 billion and is part of the health care sector. Shares are up 45.1% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Biogen Idec Ratings Report.
On the negative front,
), down 42.8%,
), down 9.9%,
), down 9.6% and
), down 7.8% , were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.